Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-9190 + peginterferon alfa-2a + ribavirin
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
GS-9190 + peginterferon alfa-2a + ribavirin is a three-drug combination developed for the treatment of chronic hepatitis C virus (HCV) infection. **GS-9190** (also known as tegobuvir) is a non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase. **Peginterferon alfa-2a** is a pegylated form of interferon alfa-2a, an immunomodulatory cytokine that enhances the antiviral response by stimulating immune cells, while **ribavirin** is a nucleoside analog with broad-spectrum antiviral activity, commonly used in combination regimens for HCV. This combination targets viral replication at multiple points: GS-9190 directly inhibits the viral polymerase, peginterferon alfa-2a stimulates the host immune system to clear infected cells, and ribavirin increases antiviral effect via multiple poorly defined mechanisms. GS-9190 was developed by Gilead Sciences as an investigational drug for HCV, but clinical development was discontinued, while peginterferon alfa-2a and ribavirin are well-established agents for HCV treatment[1][2].
- Other names
- peginterferon alfa-2aribavirin
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)RdRp (Coronavirus RNA-dependent RNA polymerase)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on GS-9190 + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-9190 + peginterferon alfa-2a + ribavirin.